These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7819590)

  • 21. Epidermal growth factor receptor-targeted cytotoxin inhibits neointimal hyperplasia in vivo. Results of local versus systemic administration.
    Pastore CJ; Isner JM; Bacha PA; Kearney M; Pickering JG
    Circ Res; 1995 Sep; 77(3):519-29. PubMed ID: 7641322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotoxins: is there a clinical value?
    Gottstein C; Winkler U; Bohlen H; Diehl V; Engert A
    Ann Oncol; 1994; 5 Suppl 1():97-103. PubMed ID: 7826425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antagonism between epidermal growth factor and phorbol ester tumor promoters in human breast cancer cells.
    Osborne CK; Hamilton B; Nover M; Ziegler J
    J Clin Invest; 1981 Apr; 67(4):943-51. PubMed ID: 6259217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant immunotoxins in targeted cancer cell therapy.
    Reiter Y
    Adv Cancer Res; 2001; 81():93-124. PubMed ID: 11430597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant immunotoxins for treating cancer.
    FitzGerald DJ; Kreitman R; Wilson W; Squires D; Pastan I
    Int J Med Microbiol; 2004 Apr; 293(7-8):577-82. PubMed ID: 15149034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy.
    Berstad MB; Cheung LH; Berg K; Peng Q; Fremstedal AS; Patzke S; Rosenblum MG; Weyergang A
    Oncogene; 2015 Oct; 34(44):5582-92. PubMed ID: 25684137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotoxins: a clinical review of their use in the treatment of malignancies.
    Hertler AA; Frankel AE
    J Clin Oncol; 1989 Dec; 7(12):1932-42. PubMed ID: 2685183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells.
    Kondapaka SB; Fridman R; Reddy KB
    Int J Cancer; 1997 Mar; 70(6):722-6. PubMed ID: 9096655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotoxins.
    Kreitman RJ
    Expert Opin Pharmacother; 2000 Sep; 1(6):1117-29. PubMed ID: 11249483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468.
    Modjtahedi H; Styles JM; Dean CJ
    Br J Cancer; 1993 Feb; 67(2):247-53. PubMed ID: 8094290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers.
    Simon N; FitzGerald D
    Toxins (Basel); 2016 May; 8(5):. PubMed ID: 27153091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effective targeted cytotoxicity of neuroblastoma cells.
    Thomas PB; Delatte SJ; Sutphin A; Frankel AE; Tagge EP
    J Pediatr Surg; 2002 Mar; 37(3):539-44. PubMed ID: 11877684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal growth factor expression in human colon and colon carcinomas: anti-sense epidermal growth factor receptor RNA down-regulates the proliferation of human colon cancer cells.
    Rajagopal S; Huang S; Moskal TL; Lee BN; el-Naggar AK; Chakrabarty S
    Int J Cancer; 1995 Sep; 62(6):661-7. PubMed ID: 7558411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autocrine stimulation of a human lung mesothelioma cell line is mediated through the transforming growth factor alpha/epidermal growth factor receptor mitogenic pathway.
    Mórocz IA; Schmitter D; Lauber B; Stahel RA
    Br J Cancer; 1994 Nov; 70(5):850-6. PubMed ID: 7947089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F.
    Woitok M; Klose D; Niesen J; Richter W; Abbas M; Stein C; Fendel R; Bialon M; Püttmann C; Fischer R; Barth S; Kolberg K
    Cancer Lett; 2016 Oct; 381(2):323-30. PubMed ID: 27502168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
    Foss FM
    Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peptide toxins directed at the matrix dissolution systems of cancer cells.
    Frankel AE; Bugge TH; Liu S; Vallera DA; Leppla SH
    Protein Pept Lett; 2002 Feb; 9(1):1-14. PubMed ID: 12141918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotoxins and cytokine toxin fusion proteins.
    Strom TB; Anderson PL; Rubin-Kelley VE; Williams DP; Kiyokawa T; Murphy JR
    Semin Immunol; 1990 Nov; 2(6):467-79. PubMed ID: 2104283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia.
    Kreitman RJ; Chaudhary VK; Waldmann TA; Hanchard B; Cranston B; FitzGerald DJ; Pastan I
    Leukemia; 1993 Apr; 7(4):553-62. PubMed ID: 8464234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.